Mirati Therapeutics to Report Fourth Quarter and Full Year Financial Results for 2022 and Recent Corporate Updates on February 28, 2023

Rhea-AI Summary

Mirati Therapeutics, Inc. (NASDAQ: MRTX) will announce its fourth quarter and full year financial results for 2022 on February 28, 2023. A conference call is scheduled for 4:30 p.m. ET, where executives will discuss the results and recent corporate updates. Interested parties can access the call via a live webcast or by dialing in. As a targeted oncology company, Mirati focuses on developing therapies for high unmet needs in cancer treatment, particularly in lung cancer. The company emphasizes innovation and aims to deliver transformative therapies for patients.

Positive

• Scheduled conference call for Q4 and full-year 2022 results may boost investor confidence.
• Focus on targeted oncology and unmet needs highlights potential for growth.

Negative

• None.

SAN DIEGO, Feb. 14, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a targeted oncology company, will announce financial results for the fourth quarter and full year of 2022 along with recent corporate updates on February 28, 2023. During a conference call at 4:30 p.m. ET / 1:30 p.m. PT on February 28, company executives will provide company updates and review financial results.

Investors and the general public are invited to listen to a live webcast of the call at the "Investors and Media" section on Mirati.com or by dialing the U.S. toll free +1 773-305-6853 or international +1 888-394-8218, confirmation code: 2312901. A replay of the call will be available approximately 2 hours after the event has ended at the same website.

About Mirati Therapeutics, Inc.  

Mirati Therapeutics, Inc. is a biotechnology company whose mission is to discover, design and deliver breakthrough therapies to transform the lives of patients with cancer and their loved ones. The company is relentlessly focused on bringing forward therapies that address areas of high unmet need, including lung cancer, and advancing a pipeline of novel therapeutics targeting the genetic and immunological drivers of cancer. Unified for patients, Mirati's vision is to unlock the science behind the promise of a life beyond cancer.

For more information about Mirati, visit us at Mirati.com or follow us on Twitter, LinkedIn, and Facebook.

Forward Looking Statements

This press release includes forward-looking statements regarding Mirati's business, financial guidance and the therapeutic and commercial potential of KRAZATI^TM (adagrasib), sitravatinib (TAM receptor inhibitor), MRTX1719 (MTA-cooperative PRMT5 inhibitor), MRTX0902 (SOS1 inhibitor), and MRTX1133 (selective KRAS^G12D inhibitor), Mirati's technologies and Mirati' other products in development. Any statement describing Mirati's goals, expectations, intentions or beliefs, financial or other projections, is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, including those related to the impact COVID-19 could have on our business, and including those inherent in the process of discovering, developing and commercializing medicines that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such medicines.

Mirati's forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Mirati's forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Mirati. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Mirati's programs are described in additional detail in Mirati' annual report on Form 10-K, and most recent Form 10-Q, which are on file with the Securities and Exchange Commission and available at the SEC's Internet site (www.sec.gov). These forward-looking statements are made as of the date of this press release, and Mirati assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law.

Mirati Contacts

Investor Relations: ir@mirati.com

Media Relations: media@mirati.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/mirati-therapeutics-to-report-fourth-quarter-and-full-year-financial-results-for-2022-and-recent-corporate-updates-on-february-28-2023-301746781.html

SOURCE Mirati Therapeutics, Inc.

FAQ

When will Mirati Therapeutics report its financial results for 2022?

Mirati Therapeutics will report its financial results for the fourth quarter and full year of 2022 on February 28, 2023.

How can I listen to the Mirati conference call on February 28, 2023?

You can listen to the conference call via a live webcast on Mirati's website or by calling +1 773-305-6853 (U.S. toll-free) or +1 888-394-8218 (international).

What is the focus of Mirati Therapeutics?

Mirati Therapeutics is a biotechnology company focused on discovering and developing breakthrough therapies for cancer, particularly targeting genetic and immunological drivers.

What are some products in development by Mirati?

Mirati is developing several products, including KRAZATI, sitravatinib, MRTX1719, MRTX0902, and MRTX1133, which target various cancer-related pathways.